The administration of G-CSF as primary prophylaxis might be considered, however, when respecting dose intensity is more clinically relevant, such as in potentially resectable metastatic colorectal cancer patients, in the case of extensive disease in vital organs and/or symptomatic sites of metastasis, or in the neoadjuvant setting. The gene discussed is CSF3; the disease is metastatic colorectal cancer.